Brief: Moberg Pharma Q2 EBITDA Loss Narrows To SEK 3.5 Mln

Moberg Pharma AB (publ)

10/08/2021 07:09

Aug 10 (Reuters) - Moberg Pharma AB (publ)  MBPH.ST :
    * MOBERG PHARMA AB INTERIM REPORT JANUARY - JUNE 2021
    * Q2 EBITDA SEK -3.5 MILLION (-5.7)
    * Q2 OPERATING PROFIT (EBIT) SEK -4.1 MILLION (-6.3)
    * Q2 PROFIT AFTER TAX SEK -3.3 MILLION (-5.2)
    * Q2 DILUTED EARNINGS PER SHARE SEK -0.08 (-0.28)
    * CEO: REGISTRATION PREPARATIONS FOR MOB-015 ARE PROGRESSING
AS
PLANNED, WITH GOAL TO SUBMIT A REGISTRATION APPLICATION IN
EUROPE IN SECOND HALF OF 2021

Source text for Eikon:  ID:nWkr5gWVpr 
Further company coverage:  MBPH.ST 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))